For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Kamada been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Kamada is one of 850 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. KMDA is currently sporting a Zacks Rank of #1 (Strong Buy).

The Zacks Consensus Estimate for KMDA's full-year earnings has moved 33.33% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the latest available data, KMDA has gained about 17.42% so far this year. In comparison, Medical companies have returned an average of 10.03%. This means that Kamada is performing better than its sector in terms of year-to-date returns.

Looking more specifically, KMDA belongs to the Medical - Biomedical and Genetics industry, which includes 355 individual stocks and currently sits at #86 in the Zacks Industry Rank. On average, stocks in this group have gained 16.29% this year, meaning that KMDA is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on KMDA as it attempts to continue its solid performance.